Funding profile · Oncology therapeutics

Reverie Labs

More than $32 million of venture capital went into an AI kinase drug discovery company that filed no Form D, registered no trial, and sold its platform for about $2.4 million of stock in a buyer that paid more to retain four of its employees.

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

Reverie Labs, Inc. never filed a Form D. EDGAR company and full text searches return only unrelated entities, and the only SEC record of its capital events sits on the buyer’s side of the final transaction.

Reading the filings

1. The absence of a Form D is itself the finding.Seven years of venture rounds produced no Regulation D notice under the company’s name. Issuers raising under Section 4(a)(2) rather than Regulation D file nothing, so the gap does not mean no money moved; it means the $32 million is documented only by press releases and databases.
2. The buyer paid more to keep the people than to buy the platform.$3,530,000 of restricted stock units went to four employees, about $882,500 each, against $2,400,000 of stock to the company. That is a ratio of 1.47 to 1 in favor of retention. It is the signature of an acquihire, and it is disclosed in a document the company itself did not have to file.
3. The stock consideration is about seven cents on the dollar raised.$2,400,000 divided by $32,000,000 is 7.5 percent, and the company’s own figure was “more than $32M”, so the true ratio is lower. Whatever the drug assets are worth, they were not in this transaction and were not priced by it.
4. Structure separates Reverie from the comparable deal.In the same 10-Q paragraph, Patch Biosciences was acquired by merger for about $14,400,000 of stock. Reverie was an asset purchase of infrastructure and software. A merger takes the whole company, pipeline included. An asset purchase takes what the buyer wants and leaves the shell holding the rest.
5. Nothing in the capital stack was non-dilutive.No NIH grant, no NSF award, no SBIR. Unlike most preclinical oncology companies, Reverie carried the full cost of its chemistry on equity, at an amortized cost the CTO put at roughly $2,000 per molecule synthesized plus several thousand in assays.
6. The milestone line was worth nothing to the next round.The CTO wrote that when the company sounded out a Series B, “it became clear that most biotech investors valued these programs at ~$0 beyond the reputation signaling that we weren’t total clowns”. A marquee Roche and Genentech collaboration did not convert into a financeable balance sheet item.

Commercial signals

What to watch

• Any Form D, and any sign the RVL assets were licensed or sold.
• A first trial registration naming RVL-101 or a CDK4/6 inhibitor traceable to it.
• Whether Roche or Genentech names a molecule from the 2020 collaboration, which would trigger the milestone terms.
• Disposition of the 1,832,172 Ginkgo shares, and whether Reverie Labs, Inc. distributes or dissolves.

The Reverie Labs story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Notable Labs: Shared investor: First Round. A blood cancer company that screened drugs against a patient’s own cells to predict who would respond, in-licensed a shelved Boehringer Ingelheim compound, reached
• 64x Bio: Shared investor: First Round. A Harvard spinout that engineers the cells which manufacture viral vectors, rather than the therapies those vectors carry
• Modern Fertility: Shared investor: First Round. A finger prick hormone panel sold to women who were not trying to conceive
• Endpoint Health: Shared investor: Wireframe Ventures. A Palo Alto company that set out to rescue sepsis drugs the field had given up on, by finding the patients they actually help

Sources

1. Public recordGinkgo Bioworks Form 10-Q, Q1 2024, Item 2SEC EDGAR · May 9, 2024
2. Public recordEDGAR company and full text search, no Form D for Reverie LabsSEC · Sep 23, 2026
3. Public recordClinicalTrials.gov search, Reverie Labs, nil returnNLM · Sep 23, 2026
4. Public recordFederal records pull, nil across FDA, NIH and NSFCompiled · Sep 23, 2026
5. CompanyGinkgo compensation information on recent acquisitionsPR Newswire · Feb 28, 2024
6. CompanyGinkgo Bioworks acquires Reverie Labs platformPR Newswire · Feb 28, 2024
7. CompanyReverie Labs raises $25M Series A roundPR Newswire · Feb 3, 2021
8. CompanyMulti-target collaboration agreement with RochePR Newswire · Jul 8, 2020
9. FounderHow unfair is the coin?Ankit Gupta, personal blog · Jan 6, 2025
10. IndependentA virtual drug discovery company with no lab of its ownSynBioBeta · Aug 25, 2020
11. IndependentBioworks company forges 3 acquisition dealsFierce Biotech · Feb 28, 2024
12. IndependentReverie Labs company profile and acquisitionTracxn · Sep 23, 2026
13. IndependentReverie Labs, Inc. pipelines and patentsPatsnap Synapse · May 8, 2025

Compiled from SEC, NIH, NSF, FDA and ClinicalTrials.gov public records and published reports as of September 23, 2026. Reverie Labs, Inc. filed no Form D; amounts for its private rounds come from company releases and third party databases and are labeled as such. Healthcare Venture Capital Fund holds no position in Reverie Labs. This page is not an offer to sell or a recommendation to buy any security.